Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer
Conditions
Lung Cancer
Conditions: official terms
Lung Neoplasms
Conditions: Keywords
lung cancer
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Intervention
Name: comparative genomic hybridization Type: Genetic
Name: gene expression microarray analysis Type: Genetic
Name: proteomic profiling analysis Type: Genetic
Name: biologic sample preservation procedure Type: Other
Name: nasal brushing Type: Procedure
Name: Blood draw Type: Procedure
Name: Urine collection Type: Procedure
Name: sputum sample Type: Procedure
Name: fluorescence bronchoscopy with airway biopsy Type: Procedure
Name: fine needle aspiration of the lung Type: Procedure
Name: thoracentesis Type: Procedure
Overall Status
Recruiting
Summary
RATIONALE: Using samples of blood, urine, sputum, and lung tissue from patients at high risk of cancer for laboratory studies may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at molecular predictors of cancer in patients at high risk of lung cancer.
Detailed Description
OBJECTIVES:

- To use fixed lung tissue for histological evaluation and fresh tissue samples for molecular studies to study DNA, RNA, and protein abnormalities in lung preneoplastic and neoplastic lesions.

- To use proteomic techniques, including matrix-assisted laser desorption ionization-mass spectrometry (MALDI-MS), to develop a method of diagnosing and staging both pre-invasive and invasive lesions, using less invasive methods.

OUTLINE: Blood, urine, nasal cell, and sputum samples are collected. Lung tissue samples are also collected using fluorescence bronchoscopy and epithelial cell collection.

Samples are studied by genetic and proteomic analyses, including comparative genomic hybridization, expression microarray, and protein profiling.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

-All adults referred to Vanderbilt Medical Center, Veterans Administration Medical Center, St. Thomas Hospital and Meharry Medical Center for evaluation of signs or symptoms of lung cancer.

Exclusion Criteria:

- Inability to provide informed consent

- Minors

- Pregnant women
Locations
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Status: Recruiting
Contact: VICC Clinical Trials Information Program - 800-811-8480
Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States
Status: Recruiting
Contact: VICC Clinical Trials Information Program - 800-811-8480
Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States
Status: Recruiting
Contact: VICC Clinical Trials Information Program - 800-811-8480
Veterans Affairs Medical Center - Nashville
Nashville, Tennessee, United States
Status: Recruiting
Contact: Research Office - 615-873-8066
Start Date
December 2003
Completion Date
January 2017
Sponsors
Vanderbilt-Ingram Cancer Center
Source
Vanderbilt-Ingram Cancer Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page